Patients receiving catalpol had significantly lower serum levels of colon cancer biomarkers of carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA), MMP-2, and MMP-9 as compared to the placebo group. Here, CEACAM5 is linked to malignant colon neoplasm.